The DOI matches its Crossref record; 113 of the 113 references it cites were found in a registry or an index.
The need for screening, early diagnosis, and prediction of chronic kidney disease in people with diabetes in low- and middle-income countries—a review of the current literature
Open accessAbstract
Chronic kidney disease (CKD) in people with diabetes is becoming an increasing major public health concern, disproportionately burdening low- and middle-income countries (LMICs). This rising burden is due to various factors, including the lack of disease awareness that results in late referral and the cost of screening and consequent treatment of the comorbid conditions, as well as other factors endemic to LMICs relating to inadequate management of risk factors. We critically assessed the extant literature, by performing searches of Medline via PubMed, EBSCOhost, Scopus, and Web of Science, for studies pertaining to screening, diagnosis, and prediction of CKD amongst adults with diabetes in LMICs, using relevant key terms. The relevant studies were summarized through key themes derived from the Wilson and Jungner criteria. We found that screening for CKD in people with diabetes is generally infrequent in LMICs. Also, LMICs are ill-equipped to appropriately manage diabetes-associated CKD, especially its late stages, in which supportive care and kidney replacement therapy (KRT) might be required. There are acceptable and relatively simple tools that can aid diabetes-associated CKD screening in these countries; however, these tools come with limitations. Thus, effective implementation of diabetes-associated CKD screening in LMICs remains a challenge, and the cost-effectiveness of such an undertaking largely remains to be explored. In conclusion, for many compelling reasons, screening for CKD in people with diabetes should be a high policy priority in LMICs, as the huge cost associated with higher mortality and morbidity in this group and the cost of KRT offers a compelling economic incentive for improving early detection of diabetes in CKD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“A TBI <0.70 is diagnostic for LEAD.747,763”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [747]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Diabetes is one of the most important risk factors for the development and progression of atherosclerosis.[747][748][749][750][751]”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [747]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The strong correlation between LEAD and diabetes is well established.[747][748][749]”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [747]
Experimental — accuracy not yet measuredIn the citing paper
“The impact of diabetes differs between vascular territories.747”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [747]
In the citing paper
“The medical management of LEAD in patients with diabetes does not differ from that recommended for patients with ASCVD in general including SGLT2 inhibitors and GLP-1 RAs.747,757,764,765”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [747]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Toprak, O., Kurt, H., Sarı, Y., Şarkış, C., Us, H., & Kırık, A. (2017) · Kidney and Blood Pressure Research · doi:10.1159/000468530 · Cited by 29,627
A New Equation to Estimate Glomerular Filtration Rate
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. (., Castro, A. F., Feldman, H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00006 · Cited by 25,603
Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., Roth, D., & for the Modification of Diet in Renal Disease Study Group* (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00002 · Cited by 15,079
International Diabetes Federation 2017
Carracher, A. M., Marathe, P. H., & Close, K. L. (2018) · Journal of Diabetes · doi:10.1111/1753-0407.12644 · Cited by 13,418
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · Nephron · doi:10.1159/000447068 · Cited by 11,717
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059 · cited 1×
“Tight glycaemic control, and the control of other risk factors like blood pressure, can prevent the occurrence and progression of microvascular complications in people with diabetes [8, 9].”
Background10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Global estimates of the prevalence of diabetes for 2010 and 2030
Shaw, J. E., Sicree, R. A., & Zimmet, P. Z. (2010) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2009.10.007 · Cited by 7,216 · cited 1×
“A common microvascular complication caused by uncontrolled chronic hyperglycaemia is diabetic nephropathy [4, 5] (also termed diabetic kidney disease [DKD]).”
Background
Research works printed but not linked: 4
- International Diabetes Federation. IDF Diabetes Atlas. 10th ed. 2021.
- Internation Diabetes Foundation. IDF Diabetes Atlas. 9th ed. 2019.
- KDIGO. KDIGO clinical practice guideline for lipid management in chronic kidney disease. Kidney Int Suppl. 2013;3:268–70.
- National Kidney Foundation. Diabetes, chronic kidney disease and special populations. 2017. Available from: https://www.kidney.org/atoz/content/diabetesckd_sppop.
Cited by
2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes.
Marx, N., Federici, M., Schütt, K., Müller-Wieland, D., Ajjan, R. A., Antunes, M. J., Christodorescu, R. M., Crawford, C., Di Angelantonio, E., Eliasson, B., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad192 · Cited by 1,642
Xu, L., Wang, Z., Li, M., & Li, Q. (2025) · Journal of Global Health · doi:10.7189/jogh.15.04156 · Cited by 60
“High-income countries benefit from early diagnosis and effective management, resulting in declining or stable incidence rates, while LMICs, constrained by limited resources, bear a significant disease burden [ 40 ].”
Makmun, A., Satirapoj, B., Tuyen, D. G., Foo, M. W. Y., Danguilan, R. A., Gulati, S., Kim, S., Bavanandan, S., Chiu, Y., & Tang, S. C. W. (2024) · Kidney Research and Clinical Practice · doi:10.23876/j.krcp.23.194 · Cited by 45
“Although quantitative assessment of albuminuria using UACR is favored and recommended by the guidelines, it is unaf-fordable in certain developing Asian countries and dip-stick screening is considered acceptable to be followed by appropriate confirmatory testing [112].”
MethodSatarug, S., Djordjević, A. B., Yimthiang, S., Vesey, D. A., & Gobe, G. C. (2022) · Toxics · doi:10.3390/toxics10100614 · Cited by 27
Zhao, C., Zhao, H., Zhang, C., Yang, X., Chen, K., Xue, Y., Li, Q., Deng, S.-Y., & Cai, H. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.10.176 · Cited by 26
Metadata
- Authors
- George, C., Echouffo-Tcheugui, J. B., Jaar, B. G., Okpechi, I. G., & Kengne, A. P.
- Affiliations
- South African Medical Research Council (ZA)
- Johns Hopkins University (US)
- University of Alberta (CA)
- Corresponding author
- George, Cindy
- Venue
- BMC Medicine
- Published
- 2022-08-02
- Volume
- 20
- Issue
- 1
- Pages
- 247-247
- ISSN
- 1741-7015 (ISSN-L)
- PMC
- PMC9344711
- OpenAlex
- W4289333437
- Cited by
- 91
- References
- 113
- Citations by year
- 2026: 15 · 2025: 21 · 2024: 30 · 2023: 14 · 2022: 4
- FWCI
- 2.59
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- BMC Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- South African Medical Research Council
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Nephrology › Dialysis and Renal Disease Management
- Keywords
- chronic kidney disease, diabetes mellitus, CKD screening, early diagnosis, risk prediction, low- and middle-income countries, renal replacement therapy, cost-effectiveness, late referral, disease awareness, Wilson and Jungner criteria
- MeSH terms
- Adult, Developing Countries, Diabetes Mellitus, Humans, Mass Screening, Early Diagnosis, Renal Insufficiency, Chronic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The need for screening, early diagnosis, and prediction of chronic kidney disease in people with diabetes in low- and middle-income countries—a review of the current literature. https://app.cochat.ai/papers/10.1186/s12916-022-02438-6
- The paper
- George, C., Echouffo-Tcheugui, J. B., Jaar, B. G., Okpechi, I. G., & Kengne, A. P. (2022). The need for screening, early diagnosis, and prediction of chronic kidney disease in people with diabetes in low- and middle-income countries—a review of the current literature. BMC Medicine. https://doi.org/10.1186/s12916-022-02438-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.